| |
Andrew C. von Eschenbach, MD |
| |
Chairman, Project FDA;
Former Director, National Cancer Institute;
Former Commissioner,
U.S. Food and Drug Administration
|
| |
|
| |
Dennis
A. Ausiello, MD |
| |
Harvard Medical School, Chief of Medicine, Massachusetts General Hospital;
Director, Pfizer, Inc. |
| |
|
| |
Arthur
Daemmrich, PhD |
| |
Assistant professor, Harvard Business School;
member of the Harvard Business School Healthcare Initiative |
| |
|
| |
Joseph
DiMasi, PhD |
| |
Director of Economic Analysis, Tufts Center for the Study of Drug Development, Tufts University |
| |
|
| |
Henry
G. Grabowski, PhD |
| |
Faculty member, Health Sector Management Program Faculty;
Professor of Economics, Director of the Program in Pharmaceuticals and Health Economics, Duke University |
| |
|
| |
Paul
Howard, PhD |
| |
Senior fellow and Director, Center for Medical Progress, Manhattan Institute;
Managing Editor, MedicalProgressToday.com |
| |
|
| |
Daniel
P. Petrylak, MD |
| |
Associate Professor of Medicine and Program Director, Genitourinary Oncology Section, Division of Hematology/Oncology, Columbia University Medical Center |
| |
|
| |
Tomas
J. Philipson, PhD |
| |
Professor, Harris School for Public Policy, University of Chicago;
Former Bush Administration Senior Economic Advisor to the head of the Food and Drug Administration (FDA) during 2003-04, and Senior Economic Advisor to the head of the Centers for Medicare and Medicaid Services (CMS) in 2004-05 |
| |
|
| |
Lance K. Stell, PhD |
| |
FACFE, John and Mary West Thatcher Professor of Philosophy, Davidson College; Clinical Professor, Department of Internal Medicine, Carolinas Medical Center;
Full Professor (Adjunct), Translational Science Institute, Wake Forest University School of Medicine
|
| |
E. Fuller Torrey, MD |
| |
Executive Director of the Stanley Medical Research Institute (SMRI) and founder of the Treatment Advocacy Center. Dr. Torrey was educated at Princeton, McGill and Stanford Universities and is the author of 20 books.
|
| |
|
| |
|
|
|
| |
FDA Approvals Are a Matter of Life and Death,
By Andrew von Eschenbach,
Wall Street Journal, 06-17-12
Toward a 21st-Century FDA,
By Andrew von Eschenbach,
Wall Street Journal, 04-15-12
Medical Innovation: How the U.S. Can
Retain Its Lead
By Andrew von Eschenbach,
Wall Street Journal, 02-14-12
PRESS RELEASE >>
|
| |
 |
| |
Why Does FDA Keep Drugmakers From Informing Doctors?, Investor's Business Daily, 01-09-13
FDA Approvals Are a Matter of Life and Death, Wall Street Journal, 06-17-12
Improving the FDA, Washington Examiner, 05-24-12
How the FDA Stifles New Cures, Part I & II, Forbes.com, 04-25-12
More on this topic >>
|
| |
|
Project FDA is a Manhattan Institute initiative that aims to reform the FDA to meet 21st century challenges. Under the
leadership of former FDA commissioner Dr. Andrew von Eschenbach, Project FDA promotes reforms that can enable the
FDA to offer a more predictable, transparent, and efficient pathway for bringing safe and effective new products to patients.
Medicine is on the cusp of a radical transformation. New sciences and technologies are poised to allow physicians to personalize
treatment for every cancer patient; arrest or prevent the development of Alzheimer's disease; and radically lower
health care costs by reducing the prevalence of expensive chronic diseases. Unfortunately, today's FDA has struggled to adapt its regulations to new scientific advances.
Project FDA believes the FDA can become a bridge for innovation, rather than a barrier to it, and that this can be achieved
without sacrificing patient safety. For instance, advances in molecular medicine that allow companies to target specific
sub-groups of patients, combined with electronic health records, should allow the FDA to streamline and improve timeconsuming
and expensive pre-market product testing that can take a decade or more, and implement vigorous post-market
surveillance of "real world" patients after drugs or devices demonstrate safety and efficacy in early testing. This approach
will not only accelerate access to innovative products; it should enhance efforts to safeguard public health.
Project FDA will educate the public on the FDA's vital role in advancing medical innovation; highlight the potential for
new sciences to improve health while also lowering costs; and collaborate with patients' groups, industry stakeholders, and
policymakers to modernize the FDA's policies and procedures.
As part of our mission to advance public dialogue and debate about the importance of supporting medical innovation and
personalized medicine, the Center for Medical Progress also hosts Medical Progress Today, a blog that provides a forum for
economists, scientists, and policy experts to explore the scientific, regulatory, and market frameworks that will best support
21st century medical innovation. |
|
